VN B101
Alternative Names: DCB-DM101Latest Information Update: 28 Aug 2021
At a glance
- Originator VitNovo
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(Adjunctive treatment) in Australia (PO, Tablet)
- 28 Jan 2020 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(Adjunctive treatment) in Taiwan (PO, Tablet)
- 07 Jun 2019 Pharmacodynamics data from a preclinical trial in Type 2 diabetes mellitus presented at the 79th Annual Scientific Sessions of the American Diabetes Association (ADA-2019)